The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The gastrointestinal peptide glucagon-like peptide 1 (GLP-1) is known to regulate consummatory behavior and is released in response to nutrient ingestion. Analogues of this peptide recently emerged as novel pharmacotherapies for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion. The findings that GLP-1 targets reward related areas including mesolimbic dopamine areas indicate that the physiological role of GLP-1 extends beyond food intake and glucose homeostasis control to include reward regulation. The present series of experiments was therefore designed to investigate the effects of the GLP-1 receptor agonist, Exendin-4 (Ex4), on established nicotine-induced effects on the mesolimbic dopamine system in mice. Specifically, we show that treatment with Ex4, at a dose with no effect per se, attenuate nicotine-induced locomotor stimulation, accumbal dopamine release as well as the expression of conditioned place preference in mice. In accordance, Ex4 also blocks nicotine-induced expression of locomotor sensitization in mice. Given that development of nicotine addiction largely depends on the effects of nicotine on the mesolimbic dopamine system these findings indicate that the GLP-1 receptor may be a potential target for the development of novel treatment strategies for nicotine cessations in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In AD, GLP-1(7-36) amide inhibits IL-1β transcription and prevents cognitive dysfunction, amyloid precursor protein synthesis, and cell death.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [425]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It also enhances learning and memory by promoting long-term potentiation (LTP).425,426”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [425]
Experimental — accuracy not yet measuredIn the citing paper
“preclinical studies suggest GLP-1 may also limit nicotine intake, although these effects of GLP-1 appear to be mediated through distinct mechanisms and brain areas.126,127”
From Nicotinic Acetylcholine Receptor Signaling in the Hypothalamus: Mechanisms Related to Nicotine’s Effects on Food Intake (2020) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,416
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346 · cited 2×
“Given that expression of locomotor sensitization has been suggested to reflect the neurochemical alterations underlying important parts of addiction such as craving and compulsive drug taking [29], GLP-1 receptors may have an important role in the development of addiction.”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“as the hypothalamus and mesolimbic areas [8-11].”
ResultThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“as the hypothalamus and mesolimbic areas [8-11].”
Resultmouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“weight [12-14] via GLP-1 receptors expressed in the hypothalamus [15] and the NTS [16].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“weight [12-14] via GLP-1 receptors expressed in the hypothalamus [15] and the NTS [16].”
BackgroundGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“Clinically available GLP-1 receptor analogues, such as exenatide and liraglutide, are approved for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion [43-46].”
BackgroundREVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview
Sanchis‐Segura, C., & Spanagel, R. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00012.x · Cited by 629 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
BackgroundDrug addiction: the neurobiology of behaviour gone awry
Volkow, N. D., & Li, T.-K. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1539 · Cited by 625 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
Cited by
Items 101–162 of 162
Gendy, M. N. S., Ibrahim, C., Sloan, M. E., & Foll, B. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_253 · Cited by 10
Kong, Q., Li, Y., Yue, J., Wu, X., & Xu, M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01043-y · Cited by 10
Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Prince, M. A., Dermody, S. S., Jordan, R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.14898 · Cited by 11
Caffrey, A., Lavecchia, E., Chichura, K. S., Hayes, M. R., Doyle, R. P., & Schmidt, H. D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70096 · Cited by 7
“…that acute administration of a GLP-1R agonist (i.e. Ex-4, liraglutide, semaglutide) attenuated cocaine, amphetamine, alcohol, and nicotine-evoked dopamine release in the NAc (Aranas et al., 2023; Egecioglu, Engel, & Jerlhag, 2013a, 2013b; Egecioglu, Steensland, et al., 2013; Vallöf et al., 2016).”
Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon
Loftén, A., Farokhnia, M., Vendruscolo, L. F., & Leggio, L. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70021 · Cited by 8
“Consistent with the alcohol data, GLP-1RAs attenuate dopamine release in the NAc induced by amphetamine [61], cocaine [53, 61], and nicotine [62].”
Edvardsson, C. E., Vestlund, J., Ericson, M., & Jerlhag, E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1439203 · Cited by 7
Self-citationTherapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation
Hendershot, C. S., Simmons, W. K., Jha, M. K., McKee, S. A., & Yammine, L. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.002 · Cited by 6
Impact of Gut and Metabolic Hormones on Feeding Reward
Klockars, A., Levine, A. S., Head, M. A., Perez‐Leighton, C. E., Kotz, C. M., & Olszewski, P. K. (2021) · Comprehensive physiology · doi:10.1002/cphy.c190042 · Cited by 6
Johnson, M., Brigande, A. M., Yue, J., Colvin, K. J., Dao, O., & Currie, P. J. (2021) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2021.119016 · Cited by 6
Łupina, M., Wąsik, A., Baranowska‐Bosiacka, I., Tarnowski, M., Słowik, T., Listos, P., Kotlinska, J. H., Kosik-Bogacka, D. I., Gutowska, I., & Listos, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053008 · Cited by 6
“In parallel, it was also evidenced that the administration of a GLP-1 analogue inhibited the rewarding effect of various addictive substances, i.e., amphetamine [24], cocaine [24,25], nicotine [26] and ethanol [27,28], in experimental animals.”
Foscue, E. P., Trinko, R., Jiménez, J. L., Kong, E., Thompson, S. L., Stankewich, K., Corstens, A. M., Serlie, M. J. M., Taylor, J. R., & Dileone, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.08.681212 · Cited by 6
“GLP-1R agonists reduce operant responding for non-food rewards, such as alcohol or drugs of abuse (Egecioglu et al., 2013c, 2013a, 2013b; Erreger et al., 2012; Herman et al., 2023; Reddy et al., 2016; Schmidt et al., 2016; Shirazi et al., 2013; Sørensen et al., 2015; Vallöf et al., 2016),…”
Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 8
Gut Hormones: Possible Mediators of Addictive Disorders?
Nestor, L. J., & Ersche, K. D. (2024) · European Addiction Research · doi:10.1159/000540743 · Cited by 5
“Importantly, GLP-1 receptors are also highly expressed throughout the mesolimbic system, where they attenuate dopamine release [66, 67].”
Barış, E., Portakal, H. S., Aslan, A., Karagonlar, Z. F., & Tosun, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04225-5 · Cited by 4
“GLP-1 receptor activation has been suggested to influence addiction-related behaviors, including nicotine dependence, through interactions with nAChRs (Egecioglu et al. 2013; Vallöf et al. 2016).”
Cerroni, C., Steiner, A., Seanez, L., Kwon, S., & Lewis, A. S. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137299 · Cited by 4
The gut and heart’s role in reward processing
Arinel, M., & Abdelaal, K. (2025) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2025.1479923 · Cited by 3
Evans, B., Acharya, N., Brandl, C. G., Shealy, E., Nyland, J. E., Freet, C. S., Bunce, S. C., & Grigson, P. S. (2026) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000880 · Cited by 4
Of mice and men: incretin actions in the central nervous system
Farr, O. M., Pilitsi, E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.05.013 · Cited by 3
Budzyński, J., Czarnecki, D., Kruszewski, M. K., Długosz, A., & Ziółkowski, M. (2024) · Medical Research Journal · doi:10.5603/mrj.101513 · Cited by 2
Will blockbuster obesity drugs revolutionize addiction treatment?
Dolgin, E. (2025) · Nature · doi:10.1038/d41586-025-03911-x · Cited by 2
GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia
Bhaduri, G., Mukherjee, S., Parikh, R. M., Karak, S., & Pal, J. (2026) · Endocrine · doi:10.1007/s12020-026-04559-x · Cited by 2
Incretin-Based Therapies: A Novel Pathway in Addiction Treatment
Rosiejka, D., Joanna, M., Marcickiewicz, J., Bogdańska, A., Błażejewska, W., & Szulińska, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041613 · Cited by 2
“Together, these findings support the hypothesis that GLP-1R activation reduces nicotine reward without inducing aversive effects [101].”
Elghanam, Y., & Kim, E. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01615-y · Cited by 3
“Moreover, it may support learning and memory by facilitating long-term potentiation (Hölscher 2010; Egecioglu et al. 2013).”
Effects of Bariatric Surgery and Obesity Medicines on Human Eating Behavior
Hernández, F. C., Villelabeitia, I. K., Levine, I., le Roux, C. W., Miras, A. D., & Price, R. K. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-070225-105258 · Cited by 2
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Sarma, I. D., Biswas, K. P., Jagdish, P., Praveen, K., Ahmed, K. A., & Saikia, D. (2026) · Cureus · doi:10.7759/cureus.111641 · Cited by 2
“This pattern suggests GLP-1RAs engage metabolic but not addiction-relevant reward circuits sufficiently to alter smoking behavior [9,10].”
Klausen, M. K., & Fink‐Jensen, A. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.07.010 · Cited by 2
Cadmium Increases the Sensitivity of Adolescent Female Mice to Nicotine-Related Behavioral Deficits
Adeniyi, P. A., Olatunji, B. P., Ishola, A. O., Ajonijebu, D. C., & Ogundele, O. M. (2014) · Behavioural Neurology · doi:10.1155/2014/360978 · Cited by 3
Kong, Q., Wu, X., & Xu, M. (2021) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2021.10007 · Cited by 1
Effects of linagliptin on morphine dependence in larval zebrafish (Danio rerio)
Łupina, M., & Listos, J. (2022) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2022-0002 · Cited by 1
GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential
Ahmed, G. U., Zehra, E., Rasheed, S., Akhtar, S. O., Raza, A. A., Mujaddadi, K., & Samadi, A. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004725 · Cited by 1
“…in certain areas of the central nervous system responsible for drug-and food-related rewarding effects, such as the ventral tegmental area and the nucleus accumbens [ 16 ] Consistent with this, GLP-1 RAs attenuate the drug reward for substances such as nicotine in animal models [ 17 , 18 ] .”
Alsaleh, N. A., Alsharif, A. A., Joharji, H., Almazyad, F. A., Alsaidy, F., Alsahli, M., Aljanadi, Q. M., Babalghaith, R., Alfawaz, S., & Alzahrani, N. J. (2026) · BMC Public Health · doi:10.1186/s12889-026-26474-6 · Cited by 1
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Hrickova, M., Demirci, S. F., Amchová, P., & Kučerová, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1791206 · Cited by 2
“…reduces cocaine-induced dopamine levels in the NAc (Egecioglu et al., 2013b; Sørensen et al., 2015; Fortin and Roitman, 2017) with similar effects on cocaine, amphetamine (Egecioglu et al., 2013b), ethanol (Sørensen et al., 2016; Vallöf et al., 2016; 2019), and nicotine (Egecioglu et al., 2013a).”
Herman, R. J., Caffrey, A., Pothikamjorn, A., Zhang, X., Fortuna, R. P., & Schmidt, H. D. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.05.002 · Cited by 2
Lista, S., Ballerio, M., López‐Ortiz, S., Khoramipour, K., Imbimbo, B. P., Santos‐Lozano, A., Minoretti, P., & Emanuele, E. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174217 · Cited by 1
Alanazi, A. S., & Alanazi, B. A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1893173 · Cited by 1
The Neuropsychoendocrinology of Substance Use Disorders
Aoun, E. G., & Schmidt, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00004-3 · Cited by 1
Effects of Chronic Electronic Vapor Exposure on Body Weight, Appetite, and Metabolism
Breit, M. J. (2017) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.5257
Gut-brain axis: Central impact of gut peptides and metabolic drug on monoamine neurotransmission
Omoloye, A. (2019) · DMU Open Research Archive (De Montfort University)
Chen, G., Ghazal, M., Rahman, S., & Lutfy, K. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2021.07.006
The Gut-Brain Axis and Addictions: A New Narrative
Jerlhag, E. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_2-1
Self-citationThe Gut-Brain Axis and Addictions: A New Narrative
Jerlhag, E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_2
Self-citationAbshire, K. M., & Leggio, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823453-2.00013-8
New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system
Łupina, M., & Listos, J. (2023) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2023-0040
A current grasp of GLP-1 receptor agonists for addiction: emerging therapeutic potential
Moosa-Battey, R. (2025) · SA pharmaceutical journal. · doi:10.36303/sapj.2615 · Cited by 1
Bremmer, M. P., Courtney, J. B., Neilson, A. P., Burger, K. S., Thiele, T. E., & Hendershot, C. S. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06980-y
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671494
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671485
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671491
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671497
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671488
Santos, V. D. D. S., Neves, T. D. A., BRANCO, M. G. B. C., de Almeida, R. V., de Oliveira, A. B. S., Ferreira, L. D. F., cruz, D. L. L., Costa, M. M. M. D. O., Puget, R. F., Kimura, L. C. D. F., et al. (2026) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2026v8n3p352-361
Iceta, S. (2019) · theses.fr (ABES) · doi:10.70675/36d565a6z696az485fz8ee5z8e40d0ba56b2 · Cited by 2
Medication assisted treatment for substance use disorder
Naeem, M., & Iqbal, A. (2026) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.31816
Role of incretins in Alzheimer’s disease and their impact on behavioral aspects
Yang, J., Mao, T., & Gao, L. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004195
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Pucek, W. F., Hoffmann, K., Bryl, W., Kus, K., & Paczkowska, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1906959
Edvardsson, C. E., Emous, T. A., Witley, S., Ericson, M., Adermark, L., & Jerlhag, E. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70678 · Cited by 1
Self-citationZheng, Y. J., Au, H. C. T., Le, G. H., Wong, S., Teopiz, K. M., Kwan, A. T. H., Rosenblat, J. D., Mansur, R. B., Rhee, T. G., Lo, H. K. Y., et al. (2026) · Acta Neuropsychiatrica · doi:10.1017/neu.2026.10097
“EX4 pretreatment (2.4 μ g/kg) reduced nicotine-induced locomotor stimulation (nicotine administration: 0.5 mg/kg) ( P 0.01), although EX4 alone did not produce a significant reduction compared to the vehicle group ( P > 0.05) (Egecioglu et al ., 2013a).”
InfluentialEffect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation
Sailer, C. O., Lengsfeld, S., Coynel, D., Zanchi, D., Jeanloz, N., Baur, F., Bathelt, C., Bologna, K., Vukajlovic, T., Urwyler, S. A., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag410
Reber, V., Müller, C., Lengsfeld, S., Probst, L., Werlen, L., Allen, R., Emara, Y., Bathelt, C., & Winzeler, B. F. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70308
Metadata
- Authors
- Egecioglu, E., Engel, J. A., & Jerlhag, E.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Engel, Jörgen A.
- ORCID
- Jerlhag, Elisabet
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-18
- Volume
- 8
- Issue
- 10
- Pages
- e77284
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3799694
- OpenAlex
- W2086172137
- Cited by
- 158
- References
- 52
- Citations by year
- 2026: 22 · 2025: 20 · 2024: 15 · 2023: 18 · 2022: 10 · 2021: 18 · 2020: 5 · 2019: 17 · 2018: 6 · 2017: 2 · 2016: 14 · 2015: 6 · 2014: 5
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Vetenskapsrådet (K2010-80X-21496-01-6, 2009-02782, K2006-21X-04247-33-3)
- Sahlgrenska Universitetssjukhuset (148251)
- Systembolaget Aktiebolag
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- exendin-4, glucagon-like peptide-1, GLP-1 receptor agonists, nicotine, nicotine dependence, mesolimbic dopamine system, locomotor stimulation, locomotor sensitization, conditioned place preference, reward, nicotine cessation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Conditioning, Psychological, Dopamine, Eating, Limbic System, Male, Motor Activity, Nicotine, Nucleus Accumbens, Peptides, Reward, Tobacco Use Disorder, Venoms, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.